TW202546223A - 腫瘤溶解性病毒及使用其之癌症治療 - Google Patents

腫瘤溶解性病毒及使用其之癌症治療

Info

Publication number
TW202546223A
TW202546223A TW114102532A TW114102532A TW202546223A TW 202546223 A TW202546223 A TW 202546223A TW 114102532 A TW114102532 A TW 114102532A TW 114102532 A TW114102532 A TW 114102532A TW 202546223 A TW202546223 A TW 202546223A
Authority
TW
Taiwan
Prior art keywords
promoter
cxcl10
cra
surv
cancer
Prior art date
Application number
TW114102532A
Other languages
English (en)
Chinese (zh)
Inventor
小戝健一郎
渡邉真季
松田恵理子
西川路侑耶
Original Assignee
國立大學法人鹿兒島大學
日商瑟弗生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人鹿兒島大學, 日商瑟弗生物製藥股份有限公司 filed Critical 國立大學法人鹿兒島大學
Publication of TW202546223A publication Critical patent/TW202546223A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW114102532A 2024-01-22 2025-01-21 腫瘤溶解性病毒及使用其之癌症治療 TW202546223A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024-007682 2024-01-22
JP2024007682 2024-01-22

Publications (1)

Publication Number Publication Date
TW202546223A true TW202546223A (zh) 2025-12-01

Family

ID=96545359

Family Applications (1)

Application Number Title Priority Date Filing Date
TW114102532A TW202546223A (zh) 2024-01-22 2025-01-21 腫瘤溶解性病毒及使用其之癌症治療

Country Status (3)

Country Link
JP (1) JP7816735B2 (https=)
TW (1) TW202546223A (https=)
WO (1) WO2025159067A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7117087B2 (ja) * 2017-07-10 2022-08-12 株式会社Ｉｄファーマ 癌の治療組成物
CN111542601A (zh) * 2017-11-08 2020-08-14 国立大学法人鹿儿岛大学 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗)
EP3731850A4 (en) * 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
US20220251604A1 (en) * 2019-06-14 2022-08-11 Tilt Biotherapeutics Oy Oncolytic adenovirus and checkpoint inhibitor combination therapy
CN114364792B (zh) * 2019-08-09 2024-10-01 Km生物医药股份公司 溶瘤牛痘病毒

Also Published As

Publication number Publication date
WO2025159067A1 (ja) 2025-07-31
JP7816735B2 (ja) 2026-02-18
JPWO2025159067A1 (https=) 2025-07-31

Similar Documents

Publication Publication Date Title
US20230137548A1 (en) Neural stem cell-mediated cancer treatment
US7048920B2 (en) Recombinant oncolytic adenovirus for human melanoma
McCart et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes
US11806374B2 (en) Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
US11850215B2 (en) Recombinant adenoviruses and stem cells comprising same
Liu et al. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer
JP6238485B2 (ja) Ａｕｒｏｒａキナーゼプロモーターを含む増殖制御型ウイルスベクター
WO2020011754A1 (en) Chimeric vaccinia viruses
US12435110B2 (en) Adenosomes
US7371570B2 (en) Cell-specific adenovirus vector comprising EBV-specific promoter
TW202546223A (zh) 腫瘤溶解性病毒及使用其之癌症治療
US20240165175A1 (en) Muc16 promoter containing virus
EP4048798B1 (en) Adenovirus comprising a modified adenovirus hexon protein
WO2011118819A1 (ja) サービビンプロモーターを含む増殖制御型ウイルスベクターによる造血器腫瘍の遺伝子治療
WO2025202311A1 (en) Oncolytic adenovirus with controlled replication
Deng et al. Comprehensive genome editing and signaling pathway engineering evolve potent and safe adenoviral producer cell
US20220154218A1 (en) Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
WO2024251286A1 (zh) 溶瘤性hsv-1临床分离株、定向进化株、感染性克隆及应用
CN101538556B (zh) 腺病毒选择性互补复制的方法
CN116590242A (zh) 一种重组溶瘤腺病毒及其应用
CN120648751A (zh) 一种新型携载钙网蛋白的溶瘤腺病毒、应用及制备方法
Kinase Systemic Cancer Therapy with a Tumor-selective Vaccinia
CN114438128A (zh) 一种增强型溶瘤腺病毒及其应用